Nkarta, Inc. (NKTX) Stock Ticker
NKTX right now
Market factors today
Unlock the full NKTX picture
About Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX stock facts
| Ticker symbol | NKTX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $191.0M |
| CEO | Paul J. Hastings |
| Employees | 106 |
| Headquarters | South San Francisco, CA, US |
| IPO date | 2020-07-10 |
| Website | www.nkartatx.com |
What you can see for NKTX on Tickr
Live NKTX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the NKTX report.
Rankings
FAQ
What is the ticker symbol for Nkarta, Inc.?
The ticker symbol for Nkarta, Inc. is NKTX, listed on the NASDAQ.
What is NKTX?
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory…